Logotype for Koninklijke Philips N.V.

Koninklijke Philips (PHIA) CMD 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Koninklijke Philips N.V.

CMD 2026 summary

13 Apr, 2026

Strategic direction and growth ambitions

  • Entering a new phase focused on profitable growth, targeting mid-single-digit sales CAGR and mid-teens margins by 2028, with €4.5–5 billion cumulative cash generation over the period.

  • Strategy built on three pillars: focused value creation by segment, innovation growth leveraging AI and platforms, and disciplined execution with commercial excellence.

  • Segment-specific strategies emphasize organic and inorganic investments, especially in Interventional and Monitoring platforms, with North America as a core growth engine.

  • ESG ambitions for 2030 include improving 2.5 billion lives, significant emissions reductions, and embedding sustainability in business models.

  • China and other growth markets remain long-term opportunities, with a disciplined approach to capital allocation and innovation tailored to local needs.

Innovation and platform leadership

  • Accelerated innovation pipeline, including world-firsts in imaging (helium-free 3T MRI), AI-native interventional platforms (Azurion AI), and new care intelligence platforms in monitoring.

  • Platform-based approach integrates hardware, software, data, and AI, leveraging a global installed base of 2.5 million systems and reaching 80% of top hospitals.

  • Partnerships with leading clinical and technology organizations (e.g., Mayo Clinic, AWS, NVIDIA) drive co-creation and speed to market.

  • AI and data orchestration are central to future growth, enabling personalized, efficient, and scalable care across hospital and home settings.

  • Innovation expected to contribute 70–100 bps to growth acceleration, with commercial excellence adding 40–70 bps.

Financial framework and capital allocation

  • Achieved 3.1% sales CAGR and expanded Adjusted EBITA margin from 7.4% in 2022 to 12.3% in 2025, with positive cash generation and a robust balance sheet.

  • Targeting 3–4.5% sales growth in 2026, stepping up to mid-single-digit CAGR through 2028, with margin expansion from 12% to mid-teens.

  • Free cash flow target of €1.3–1.5 billion in 2026 and €4.5–5 billion cumulatively, supported by productivity programs and working capital optimization.

  • €1.5 billion new productivity program focused on cost competitiveness, lean central functions, and AI-driven efficiency.

  • Capital allocation priorities: organic growth (R&D, CapEx), stable dividend (40–50% payout), selective M&A, and periodic share buybacks.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more